We sought to explore the efficacy of lenacapavir in various combination regimens as initial and maintenance therapy for HIV.

Lenacapavir warrants further investigation as a potential antiretroviral used orally and as injection in combination with other antiretroviral drugs.

CALIBRATE is an ongoing Phase 2 open-label active-controlled study evaluating subcutaneous (SC) and oral LEN, in combination with other antiretrovirals, in ...

2 окт. 2024 г. · The primary objective of this study is to evaluate the efficacy of lenacapavir (formerly GS-6207) containing regimens in people living with human ...

Lenacapavir was generally well tolerated. Most adverse events, including injection-site reactions, were mild or moderate. Discontinuations due to injection-site ...

We designed the CALIBRATE phase 2 trial to generate exploratory clinical data to support the future development of lenacapavir-containing regimens. We ...

CALIBRATE is an ongoing, phase 2 clinical study evaluating subcutaneous (SC) or oral LEN, in combination with other antiretrovirals, in treatment-naïve people ...

The phase 3 clinical trial evaluating lenacapavir has demonstrated its efficacy in viral ... The CALIBRATE trial is an ongoing phase 2 randomized, open-label,.

19 февр. 2022 г. · Study to evaluate the safety and efficacy of lenacapavir in combination with other antiretroviral agents in people living with HIV (CALIBRATE).

Background. - Phase 3, randomized, trial with oral and subcutaneous lenacapavir, a first-in-class capsid inhibitor, versus optimized background therapy (OBT).